JP2022163013A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022163013A5 JP2022163013A5 JP2022110518A JP2022110518A JP2022163013A5 JP 2022163013 A5 JP2022163013 A5 JP 2022163013A5 JP 2022110518 A JP2022110518 A JP 2022110518A JP 2022110518 A JP2022110518 A JP 2022110518A JP 2022163013 A5 JP2022163013 A5 JP 2022163013A5
- Authority
- JP
- Japan
- Prior art keywords
- icp
- glycosylated
- antibody
- antigen
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662314940P | 2016-03-29 | 2016-03-29 | |
| US62/314,940 | 2016-03-29 | ||
| US201662361298P | 2016-07-12 | 2016-07-12 | |
| US62/361,298 | 2016-07-12 | ||
| PCT/US2017/024024 WO2017172517A1 (en) | 2016-03-29 | 2017-03-24 | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
| JP2019503385A JP7572146B2 (ja) | 2016-03-29 | 2017-03-24 | グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503385A Division JP7572146B2 (ja) | 2016-03-29 | 2017-03-24 | グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022163013A JP2022163013A (ja) | 2022-10-25 |
| JP2022163013A5 true JP2022163013A5 (https=) | 2022-11-14 |
Family
ID=58489431
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503385A Active JP7572146B2 (ja) | 2016-03-29 | 2017-03-24 | グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 |
| JP2022110518A Pending JP2022163013A (ja) | 2016-03-29 | 2022-07-08 | グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019503385A Active JP7572146B2 (ja) | 2016-03-29 | 2017-03-24 | グリコシル化免疫チェックポイントタンパク質に特異的に結合する抗体を選択する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12059474B2 (https=) |
| EP (1) | EP3436475A1 (https=) |
| JP (2) | JP7572146B2 (https=) |
| KR (2) | KR20180130541A (https=) |
| CN (1) | CN109071636A (https=) |
| WO (1) | WO2017172517A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| WO2017055404A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
| KR101928488B1 (ko) * | 2016-01-15 | 2018-12-12 | 가톨릭대학교 산학협력단 | 페록시다신을 포함하는 무혈청 배지 첨가제 조성물 및 이의 이용 |
| ES2883297T3 (es) * | 2016-03-29 | 2021-12-07 | Stcube Inc | Anticuerpos de función doble específicos para PD-L1 glucosilado y métodos de uso de los mismos |
| EP3568157A4 (en) * | 2017-01-13 | 2021-01-06 | National Research Council of Canada | PROCESS FOR THE OPTIMIZATION OF PEPTIDIC IMMUNO-EPITOPE BY GLYCOSYLATION, ASSOCIATED OPTIMIZED PEPTIDE AND ITS USE FOR CONJUGATE VACCINES |
| MY201482A (en) | 2017-04-03 | 2024-02-26 | Hoffmann La Roche | Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15 |
| EP4516809A3 (en) | 2017-04-05 | 2025-09-03 | F. Hoffmann-La Roche AG | Bispecific antibodies specifically binding to pd1 and lag3 |
| KR20200026209A (ko) * | 2017-06-06 | 2020-03-10 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1 또는 btn1a1-리간드에 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법 |
| US11525002B2 (en) | 2017-10-11 | 2022-12-13 | Board Of Regents, The University Of Texas System | Human PD-L1 antibodies and methods of use therefor |
| EP4501355A3 (en) | 2018-03-23 | 2025-04-30 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| CN119101158A (zh) | 2018-03-23 | 2024-12-10 | 得克萨斯州大学系统董事会 | 人pd-l2抗体及其使用方法 |
| SG11202009258RA (en) | 2018-03-23 | 2020-10-29 | Univ Texas | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
| CN112584901A (zh) * | 2018-04-04 | 2021-03-30 | 真和制药有限公司 | 用于阻断非糖基化的pd-1多肽之间的相互作用的方法和组合物 |
| WO2019237012A1 (en) * | 2018-06-07 | 2019-12-12 | Board Of Regents, The University Of Texas System | Detection of immune checkpoint molecules by deglycosylation |
| US11098093B2 (en) | 2019-01-07 | 2021-08-24 | Shattuck Labs, Inc. | Heterodimeric proteins for modulating gamma delta T cells |
| PH12021551475A1 (en) | 2019-01-07 | 2022-05-02 | Shattuck Labs Inc | Heterodimeric proteins for modulating gamma delta t cells |
| CN111751545A (zh) * | 2019-03-28 | 2020-10-09 | 中国科学院上海药物研究所 | 一种筛选pd-l1/pd-1检测点抑制剂的方法 |
| PH12022550247A1 (en) * | 2019-08-02 | 2022-12-19 | Janssen Biotech Inc | Materials and methods for multidirectional biotransportation |
| CN114630841A (zh) * | 2019-08-29 | 2022-06-14 | 真和制药有限公司 | 抗体以及阻断vista及其结合配偶体的相互作用 |
| TW202122420A (zh) * | 2019-08-30 | 2021-06-16 | 美商艾吉納斯公司 | 抗ｃｄ９６抗體及其使用方法 |
| CN110456079B (zh) * | 2019-09-20 | 2020-06-02 | 四川大学华西医院 | Tapbp自身抗体检测试剂在制备肺癌筛查试剂盒中的用途 |
| US20220411511A1 (en) * | 2019-09-26 | 2022-12-29 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
| EP4041768A1 (en) * | 2019-10-09 | 2022-08-17 | StCube & Co. | Antibodies specific to glycosylated lag3 and methods of use thereof |
| CN111574627A (zh) * | 2020-05-11 | 2020-08-25 | 潘宗富 | 抗vsig4单克隆抗体及其用途 |
| CN111995683B (zh) * | 2020-09-02 | 2022-03-11 | 福州迈新生物技术开发有限公司 | 抗pd-l1蛋白单克隆抗体、细胞株及其制备方法和应用 |
| CN116139275B (zh) * | 2021-11-19 | 2026-02-17 | 复旦大学 | Cd300ld抑制剂在制备预防、诊断或治疗肿瘤产品中的用途 |
| KR20240154675A (ko) * | 2022-03-16 | 2024-10-25 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1 결합 단백질 및 이의 이용 방법 |
| JP2025538171A (ja) * | 2022-11-09 | 2025-11-26 | センティ バイオサイエンシズ インコーポレイテッド | 抗原結合ドメイン及びその使用方法 |
| CN115807090B (zh) * | 2022-11-17 | 2025-06-17 | 中国医学科学院肿瘤医院 | Slamf9在肿瘤免疫治疗中的应用 |
| CN115991780B (zh) * | 2022-12-29 | 2025-06-10 | 盖普思药业(重庆)有限公司 | 一种抗人血小板胶原蛋白受体gp-vi抗体或其抗原结合片段及其应用 |
| CN118878686A (zh) * | 2024-08-13 | 2024-11-01 | 中山大学孙逸仙纪念医院 | 一种靶向糖基化pd-l1蛋白的单链抗体及其制备方法与应用 |
| CN120078878A (zh) * | 2025-03-20 | 2025-06-03 | 复旦大学附属中山医院 | Tim-3蛋白在治疗肝损伤中的应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
| US5801029A (en) | 1993-02-16 | 1998-09-01 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
| GB9506466D0 (en) | 1994-08-26 | 1995-05-17 | Prolifix Ltd | Cell cycle regulated repressor and dna element |
| US5739169A (en) | 1996-05-31 | 1998-04-14 | Procept, Incorporated | Aromatic compounds for inhibiting immune response |
| US6982323B1 (en) | 1997-12-23 | 2006-01-03 | Alexion Pharmaceuticals, Inc. | Chimeric proteins for diagnosis and treatment of diabetes |
| US20020064528A1 (en) | 2000-01-28 | 2002-05-30 | Zhenping Zhu | Antibodies specific to KDR and uses thereof |
| US6946546B2 (en) | 2000-03-06 | 2005-09-20 | Cambridge Antibody Technology Limited | Human antibodies against eotaxin |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| CA2469616A1 (en) | 2001-12-12 | 2003-06-19 | James W. Aiken | Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| US20050281815A1 (en) | 2004-02-26 | 2005-12-22 | Dani Eshel | CD40 splice variants and their uses |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| WO2006004988A2 (en) * | 2004-06-30 | 2006-01-12 | Mayo Foundation For Medical Education And Research | B7-dc binding antibody |
| US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| WO2007124361A2 (en) | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| EP2650311A3 (en) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| US20100285039A1 (en) * | 2008-01-03 | 2010-11-11 | The Johns Hopkins University | B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells |
| US8552154B2 (en) | 2008-09-26 | 2013-10-08 | Emory University | Anti-PD-L1 antibodies and uses therefor |
| EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
| US20120264917A1 (en) | 2009-05-27 | 2012-10-18 | Ablynx N.V. | Biparatopic protein constructs directed against il-23 |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| EP2542581A4 (en) | 2010-03-01 | 2014-01-22 | David Gladstone Inst | APOLIPOPROTEIN-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF |
| CN102321923B (zh) * | 2011-05-30 | 2014-04-16 | 江苏大学 | 肿瘤粘蛋白糖肽抗原决定部位的单克隆抗体库的制备方法 |
| BR112014003315A2 (pt) | 2011-08-15 | 2017-03-01 | Univ Chicago | composições e métodos relacionados a anticorpos para a proteína a estafilocócica |
| JP2015502340A (ja) | 2011-10-27 | 2015-01-22 | エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | ｉＮＫＴに対するヒト化抗体 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR20220084444A (ko) * | 2012-05-31 | 2022-06-21 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| CN104411720B (zh) | 2012-07-02 | 2018-05-11 | 协和发酵麒麟株式会社 | 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂 |
| BR112015007672A2 (pt) | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| EP3060581A4 (en) * | 2013-10-25 | 2017-06-07 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| SG10201804945WA (en) | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| JP2017507900A (ja) | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| US20170106065A1 (en) | 2013-12-31 | 2017-04-20 | Bavarian Nordic A/S | Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| WO2016160792A1 (en) | 2015-03-30 | 2016-10-06 | Stcube & Co., Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| ES2895034T3 (es) | 2015-10-02 | 2022-02-17 | Hoffmann La Roche | Anticuerpos anti-PD1 y procedimientos de uso |
| EP3383911B1 (en) | 2015-12-02 | 2021-01-20 | STCube & Co. Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| JP7003036B2 (ja) | 2015-12-02 | 2022-02-04 | エスティーキューブ，インコーポレイテッド | グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法 |
-
2017
- 2017-03-24 CN CN201780027804.2A patent/CN109071636A/zh active Pending
- 2017-03-24 EP EP17715880.5A patent/EP3436475A1/en active Pending
- 2017-03-24 US US16/086,574 patent/US12059474B2/en active Active
- 2017-03-24 KR KR1020187031149A patent/KR20180130541A/ko not_active Ceased
- 2017-03-24 JP JP2019503385A patent/JP7572146B2/ja active Active
- 2017-03-24 KR KR1020237005614A patent/KR102778941B1/ko active Active
- 2017-03-24 WO PCT/US2017/024024 patent/WO2017172517A1/en not_active Ceased
-
2022
- 2022-07-08 JP JP2022110518A patent/JP2022163013A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022163013A5 (https=) | ||
| KR102602417B1 (ko) | G-단백질 커플화 수용체를 표적화하는 항체 및 이의 사용 방법 | |
| JP5457009B2 (ja) | ヒトに適合したモノクローナル抗体における使用法 | |
| JP6199935B2 (ja) | トロポニンｉに対する抗体およびこれらの使用法 | |
| JP6391574B2 (ja) | 種間標的内交差反応性を有する抗体分子を産生する方法 | |
| US20080003617A1 (en) | Methods for the identification and the isolation of epitope specific antibodies | |
| JP2011526249A5 (https=) | ||
| CN110573526B (zh) | 蜂王浆主蛋白的抗体及其用途 | |
| JP2017524362A5 (https=) | ||
| JP2021512604A5 (https=) | ||
| WO2001031065A1 (en) | Humanization of non-human, mammalian antibodies | |
| JP2023520969A5 (https=) | ||
| TW202434888A (zh) | 用於偵測及測定包括生物流體在內之流體中之蛋白質結構及穩定性的方法 | |
| WO2025077519A1 (zh) | 抗人tigit抗体或其功能性片段及其应用 | |
| JP2016529213A5 (https=) | ||
| WO2001030393A2 (en) | Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products | |
| JP7424718B2 (ja) | 抗原の処理方法。 | |
| JP2019513004A5 (https=) | ||
| CN109336973B (zh) | 抗转铁蛋白抗体及其用途 | |
| JP6785372B2 (ja) | 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ | |
| WO2019077951A1 (ja) | Ｍｕｃ１に対する抗体またはその抗原結合断片、それらのコード遺伝子、およびその用途 | |
| WO2025213712A1 (zh) | 基于ai从头设计筛选合成的her2蛋白特异性结合抗体及其应用 | |
| CN116162158B (zh) | 结合bp特异性抗原肽的人源抗体、制备方法及用途 | |
| CN117586397A (zh) | 抗人cd147的单克隆抗体、表达载体、细胞株及其应用 | |
| Ma et al. | Generation and optimisation of antibodies for biosensor applications |